Merck's Phase 3 Trials of HIV-1 Treatment Meet Primary Endpoint
October 25 2021 - 7:45AM
Dow Jones News
By Dave Sebastian
Merck & Co. said two Phase 3 trials of a combination pill
for adults with HIV-1 infection met their primary efficacy
endpoint.
The drugmaker on Monday said that at 48 weeks, the trials met
their safety and efficacy endpoints in adults with HIV-1 infection
currently on antiretroviral therapy. The endpoint is defined as a
percentage of participants with HIV-1 RNA levels of more than 50
copies per milliliter, the company said.
Merck said the first trial evaluated a switch from
antiretroviral therapy to doravirine/islatravir. The second trial
evaluated a switch from bictegravir/emtricitabine/tenofovir to
doravirine/islatravir, the company said.
Merck said it will present detailed findings from the studies at
a future scientific congress.
"We will continue to study doravirine/islatravir in diverse
populations of people living with HIV and look forward to sharing
data from these trials," said Joan Butterton, a vice president at
Merck Research Laboratories.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 25, 2021 07:30 ET (11:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024